Wells Fargo & Company Sonoma Pharmaceuticals, Inc. Transaction History
Wells Fargo & Company
- $410 Billion
- Q1 2024
A detailed history of Wells Fargo & Company transactions in Sonoma Pharmaceuticals, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 122 shares of SNOA stock, worth $31. This represents 0.0% of its overall portfolio holdings.
Number of Shares
122
Previous 105
16.19%
Holding current value
$31
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding SNOA
# of Institutions
16Shares Held
164KCall Options Held
0Put Options Held
0-
Susquehanna International Group, LLP Bala Cynwyd, PA46.1KShares$11,9730.0% of portfolio
-
Geode Capital Management, LLC Boston, MA35.8KShares$9,3020.0% of portfolio
-
State Street Corp Boston, MA24.3KShares$6,3210.0% of portfolio
-
Xtx Topco LTD London, X016.5KShares$4,2800.0% of portfolio
-
Two Sigma Securities, LLC New York, NY13.5KShares$3,5020.0% of portfolio
About Sonoma Pharmaceuticals, Inc.
- Ticker SNOA
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 3,100,940
- Market Cap $806K
- Description
- Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, and internationally. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription ...